MODEL-AD
The MODEL-AD consortium consisting of a Center at Indiana University School of Medicine, The Jackson Laboratory, Sage Bionetworks and the University of Pittsburgh School of Medicine, and a Center at the University of California Irvine has been established by the National Institute on Aging.
![model-ad-logo-1 A large version of the MODL-AD logo, with the text "Model organism development & evaluation for late-onset Alzheimer's Disease"](https://www.model-ad.org/files/2023/08/model-ad-logo-1.jpg)
Goals of the MODEL-AD Consortium are:
- Develop the next generation of in vivo AD models based on human data
- Institute a standardized and rigorous process for characterization of animal models
- Align the pathophysiological features of AD models with corresponding stages of clinical disease using translatable biomarkers
- Establish guidelines for rigorous preclinical testing in animal models
- Ensure rapid availability of animal models, protocols and validation data to all researchers for preclinical drug development
Screening the Optimal Pharmaceutical for Alzheimer’s Disease (STOP-AD) is a program that offers preclinical screening of compounds through the MODEL-AD Preclinical Testing Core.
The MODEL-AD Consortium is a collaboration of:
![university-indiana-logo](https://www.model-ad.org/files/2023/08/university-indiana-logo.jpg)
![jax-logo](https://www.model-ad.org/files/2023/08/jax-logo.jpg)
![sage-logo](https://www.model-ad.org/files/2023/08/sage-logo.jpg)
![uci-logo](https://www.model-ad.org/files/2023/08/uci-logo.jpg)
![pit-logo](https://www.model-ad.org/files/2023/08/pit-logo.jpg)